Diabetic Nephropathies: Clinical Trials

65 trials for Diabetic Nephropathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed, 12 unknown, 5 not yet recruiting, 4 terminated. 65 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 465Completed 41, Unknown 12, Not yet recruiting 5, Terminated 4, Recruiting 2, Active not recruiting 1

Follow Diabetic Nephropathies: new trials by email Literature Review of Diabetic Nephropathies trials Research Report on Diabetic Nephropathies

Trials (filtered) newest first · largest first

All 65 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
Naoxintong Capsule, Placebo - Diabetic Nephropathy
Phase 4Not yet recruitingChen Xiangmei4102027-03-012026-07-13
Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication - Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Phase 4Not yet recruitingUniversity of Michigan6002026-11-012026-10-21
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Finerenone 10 MG, Empagliflozin 10 MG - Diabetic Kidney Disease
Phase 4Not yet recruitingWashington D.C. Veterans Affairs Medical Center302026-10-012026-08-21
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
Finerenone, Spironolactone (drug) - Heart Failure, Diabetic Kidney Disease
Phase 4Not yet recruitingHospital de Messejana Dr. Carlos Alberto Studart Gomes602026-04-012026-05-13
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
ACE Reno - Hypertensive Nephropathy, Auto Immune Disorders
Phase 4RecruitingAce Cells Lab Limited3002025-09-202025-09-23
Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
Keluoxin Capsules, Keluoxin Capsule Simulants, Irbesartan - Diabetic Kidney Disease, Diabetic Retinopathy
Phase 4Not yet recruitingChinese PLA General Hospital4602024-10-012024-10-28
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
dapagliflozin, ACE inhibitor - Diabetic Kidney Disease, Type 1 Diabetes
Phase 4UnknownThe First Affiliated Hospital with Nanjing Medical University542024-07-012024-08-01
Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
Pirfenidone, Placebo - Diabetic Nephropathies, Type 2 Diabetes
Phase 4CompletedSidrah Lodhi602024-03-102025-03-11
Mechanism of SGLT2 Inhibition in the Kidney
SGLT2 inhibitor - Type 2 Diabetes, Diabetic Kidney Disease
Phase 4RecruitingUniversity of Michigan202024-01-012026-06-11
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg - Diabetes Mellitus, Diabetic Kidney Disease
Phase 4CompletedAmsterdam UMC, location VUmc412023-07-032026-04-15
Efficacy and Safety of Telmisartan Compared With Losartan
telmisartan, Losartan - Diabetic Nephropathies, Hypertension
Phase 4UnknownChong Kun Dang Pharmaceutical982023-04-192024-05-28
Basal Plus GLP1-ra on Glycemic Variability in CKD
Dulaglutide, Insulin Degludec, Continuous glucose monitor - Diabetes Mellitus, Diabetic Kidney Disease
Phase 4CompletedElaine Chow952022-01-282024-12-03
Study of Roxadustat's Effect on Anemia in Patients With Diabetic Kidney Disease
Roxadustat - Diabetic Kidney Disease, Anemia
Phase 4CompletedSecond Xiangya Hospital of Central South University1242021-11-022026-01-26
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Ertugliflozin 15 mg - Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Phase 4CompletedAmsterdam UMC, location VUmc402020-12-102023-05-01
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Empagliflozin 10 MG, Losartan 50Mg Tab, Placebo - Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Phase 4CompletedAmsterdam UMC, location VUmc242020-11-042021-10-08
Pentoxifylline in Diabetic Kidney Disease
Pentoxifylline, Placebo - Diabetic Kidney Disease
Phase 4Active not recruitingVA Office of Research and Development23762019-11-182026-11-05
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
SGLT2 Inhibition - Type 2 Diabetes, Diabetic Nephropathy
Phase 4UnknownZhongshan Hospital Xiamen University702019-10-152019-10-21
Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
SGLT2 inhibitor, ACE inhibitor - Diabetic Nephropathies
Phase 4UnknownNahla H Tohami602018-06-202020-04-21
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22) - Type2 Diabetes
Phase 4UnknownM.H.H. Kramer662017-11-092022-01-14
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
sodium bicarbonate - Type 1 Diabetes, Diabetic Nephropathy
Phase 4CompletedUniversity of Colorado, Denver452017-01-012026-06-17

Showing 20 of 65. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (17)  ·  Diabetes Mellitus (13)  ·  Hypertension (8)  ·  Albuminuria (7)  ·  Kidney Diseases (5)  ·  Proteinuria (5)  ·  Renal Insufficiency, Chronic (5)  ·  Diabetes Mellitus, Type 1 (4)  ·  Cardiovascular Diseases (2)  ·  Diabetes Complications (2)  ·  Hyperkalemia (2)  ·  Kidney Failure, Chronic (2)  ·  Renal Insufficiency (2)  ·  Vascular Diseases (2)

Broader conditions

Endocrine System Diseases (65)  ·  Female Urogenital Diseases (65)  ·  Female Urogenital Diseases and Pregnancy Complications (65)  ·  Male Urogenital Diseases (65)  ·  Urogenital Diseases (65)  ·  Urologic Diseases (65)  ·  Diabetes Complications (63)  ·  Kidney Diseases (60)  ·  Diabetes Mellitus (52)  ·  Metabolic Diseases (33)  ·  Nutritional and Metabolic Diseases (33)  ·  Glucose Metabolism Disorders (31)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Cardiovascular Diseases (12)  ·  Signs and Symptoms (12)

Interventions

Losartan (5)  ·  Valsartan (5)  ·  Ramipril (4)  ·  Telmisartan (4)  ·  Hydrochlorothiazide (3)  ·  Lisinopril (3)  ·  Spironolactone (3)  ·  empagliflozin (3)  ·  Angiotensin-Converting Enzyme Inhibitors (2)  ·  Aspirin (2)  ·  Cilostazol (2)  ·  Gliclazide (2)  ·  Irbesartan (2)  ·  Linagliptin (2)  ·  Liraglutide (2)

Sponsors

Amsterdam UMC, location VUmc (5)  ·  Boehringer Ingelheim (3)  ·  Peter Rossing (3)  ·  Steno Diabetes Center Copenhagen (3)  ·  Gulhane School of Medicine (2)  ·  M.H.H. Kramer (2)  ·  Novartis (2)  ·  University of Michigan (2)  ·  AHEPA University Hospital (1)  ·  Ace Cells Lab Limited (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Baker Heart and Diabetes Institute (1)  ·  Chen Xiangmei (1)  ·  Chinese PLA General Hospital (1)  ·  Chinese University of Hong Kong (1)

Countries

United States (10)  ·  China (9)  ·  Denmark (9)  ·  Netherlands (9)  ·  South Korea (5)  ·  Australia (3)  ·  Canada (3)  ·  Japan (3)  ·  Switzerland (3)  ·  Brazil (2)  ·  Egypt (2)  ·  France (2)  ·  Italy (2)  ·  Spain (2)  ·  Taiwan (2)

Top investigators

Peter Rossing, MD (2)  ·  Alireza Esteghamati, MD (1)  ·  BeomSeok Kim, M.D, Ph.D (1)  ·  Brian Callaghan, MD (1)  ·  D.S Choi, MD, PhD (1)  ·  Daniel van Raalte, MD PhD (1)  ·  David J Leehey (1)  ·  David ZI Cherney, MD, PhD (1)  ·  Dr. Alaa Abdelkarim M Fouad, MRCPUK SEC (1)  ·  Dr. Gudrun Caspar-Bell, MD (1)  ·  Edmund J Lewis, MD (1)  ·  Erling B Pedersen, Professor (1)

Results publications

PMID 38682786, PMID 35224730, PMID 38449081, PMID 38770818, PMID 39963952, PMID 41665872, PMID 11128341, PMID 16123474, PMID 16316360, PMID 18496508, PMID 20413516, PMID 20966122, PMID 22792314, PMID 22981148, PMID 22995802, PMID 24159603, PMID 24866870, PMID 25186534, PMID 27733159, PMID 27753201, PMID 28341782, PMID 28408434, PMID 28449402, PMID 31816432, PMID 32200854, PMID 32340841, PMID 32516291, PMID 32900785, PMID 33107592, PMID 33205810, PMID 34271948, PMID 34400461, PMID 35221224, PMID 35322793, PMID 35998283, PMID 36127497, PMID 36342964, PMID 36344978, PMID 37171199, PMID 37752566, PMID 37916745, PMID 38365853, PMID 39434255, PMID 42216096, PMID 42911768

NIH funding

2015 (2), 2009 (1), 2014 (1)